Hodgkin Lymphoma: Assay may predict post-transplantation relapse, possibly guiding non-transplant options
from Cancer Therapy Advisor
A new and novel genetic assay offers the possibility of predicting autologous stem cell transplantation (ASCT) outcomes for patients with relapsed classical Hodgkin lymphoma, according to its developers. Perhaps even more importantly, the authors of a new study wrote, the gene expression-based prognostic model dubbed RHL30 has the potential to provide powerful insights for the selection of treatment strategies catered to the individual patient.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063